Inhibition of isoniazid-induced expression of Mycobacterium tuberculosis antigen 85 in sputum: potential surrogate marker in tuberculosis chemotherapy trials.
Mycobacterium tuberculosis antigen 85 is induced in vitro by isoniazid (INH); its sustained induction in sputum during tuberculosis (TB) therapy predicts relapse. In this trial, rifampin or rifalazil inhibited the induction of sputum antigen 85 by INH in a dose-dependent fashion. This approach may facilitate the evaluation of new TB drugs.
University of Medicine and Dentistry-New Jersey Medical School, Newark, New Jersey 07103-2757, USA. wallisrs@umdnj.edu
R S
RS
Wallis
M
M
Phillips
J L
JL
Johnson
L
L
Teixeira
L M
LM
Rocha
E
E
Maciel
L
L
Rose
C
C
Wells
M
M
Palaci
R
R
Dietze
K
K
Eisenach
J J
JJ
Ellner
D000217:Acyltransferases; D000904:Antibiotics, Antitubercular / Q000627:therapeutic use; D000942:Antigens, Bacterial / Q000096:biosynthesis*; D000995:Antitubercular Agents / Q000494:pharmacology*; D015415:Biomarkers / Q000032:analysis; D015169:Colony Count, Microbial; D006801:Humans; D007538:Isoniazid / Q000494:pharmacology*; D007700:Kinetics; D012008:Recurrence; D012293:Rifampin / Q000627:therapeutic use; D012294:Rifamycins / Q000627:therapeutic use; D013183:Sputum / Q000187:drug effects* / Q000378:metabolism / Q000382:microbiology; D014376:Tuberculosis / Q000188:drug therapy* / Q000378:metabolism / Q000382:microbiology
D000904:Antibiotics, Antitubercular; D000942:Antigens, Bacterial; D000995:Antitubercular Agents; D015415:Biomarkers; D012294:Rifamycins; C068980:KRM 1648; D000217:Acyltransferases; C112580:antigen 85A, Mycobacterium tuberculosis; D007538:Isoniazid; D012293:Rifampin